Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Depreciation & Amortization (CF) (2016 - 2025)

Mimedx (MDXG) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $572000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 1.42% to $572000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 24.69% year-over-year, with the annual reading at $14.9 million for FY2025, 146.33% up from the prior year.
  • Depreciation & Amortization (CF) hit $572000.0 in Q4 2025 for Mimedx, roughly flat from $572000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.3 million in Q2 2021 to a low of $558000.0 in Q1 2024.
  • Historically, Depreciation & Amortization (CF) has averaged $754473.7 across 5 years, with a median of $687000.0 in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): plummeted 41.06% in 2021 and later grew 1.42% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $973000.0 in 2021, then fell by 18.19% to $796000.0 in 2022, then fell by 23.24% to $611000.0 in 2023, then fell by 7.69% to $564000.0 in 2024, then increased by 1.42% to $572000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for MDXG at $572000.0 in Q4 2025, $572000.0 in Q3 2025, and $558000.0 in Q2 2025.